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Abstract
We herein disclose a series of compounds with potent inhibitory activities towards histone 
deacetylases (HDAC) and cyclooxygenases (COX). These compounds potently inhibited the 
growth of cancer cell lines consistent with their anti-COX and anti-HDAC activities. While 
compound 2b showed comparable level of COX-2 selectivity as celecoxib, compound 11b 
outperformed indomethacin in terms of selectivity towards COX-2 relative to COX-1. An 
important observation with our lead compounds (2b, 8, 11b, and 17b) is their enhanced 
cytotoxicity towards androgen dependent prostate cancer cell line (LNCaP) relative to androgen 
independent prostate cancer cell line (DU-145). Interestingly, compounds 2b and 17b arrested the 
cell cycle progression of LNCaP in the S-phase, while compound 8 showed a G0/G1 arrest, similar 
to SAHA. Relative to SAHA, these compounds displayed tumor-selective cytotoxicity as they 
have low anti-proliferative activity towards healthy cells (VERO); an attribute that makes them 
attractive candidates for drug development.
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INTRODUCTION
Aberrant epigenetic regulation and inflammation play significant roles in tumor development 
and progression. Posttranslational acetylation and deacetylation of histones, both epigenetic 
events regulated by histone acetyl transferases (HAT) and histone deacetylases (HDAC), 
respectively, control the expression and/or silencing of tumor suppressor genes1. While these 
two epigenetic regulators exist in equilibrium in non-transformed cells, HDAC activity 
predominates in most malignant tumors, effectively leading to silencing of tumor suppressor 
genes and uncontrolled proliferation of cancer cells2. Eighteen isoforms of HDAC are 
known, eleven of which depend on zinc for their catalytic activities and are group into: class 
I (HDACs 1–3 and 8); class II (subdivided into class II A (HDACs 4, 5, 7 and 9) and class 
IIB (HDACs 6 and 10)); and class IV (HDAC 11)3. Class III HDACs, also known as sirtuins, 
are non-zinc dependent and require NAD+ for their catalytic activity3b. The expression 
profiles of HDAC isoforms in different tumors vary with each isoform playing unique roles 
in driving tumorigenesis4. The therapeutic potential of HDAC inhibition has been validated 
by the US food and drugs administration’s (FDA) approval of HDAC inhibitors (HDACi), 
vorinostat, romidepsin, belinostat and panabinostat (Figure 1) for the treatment of cutaneous 
T-cell lymphoma, peripheral T-cell lymphoma and multiple myeloma5. Cardiotoxicity, short 
half-life, and inactivity towards solid tumors are few of many challenges faced by HDACi in 
the clinic3a, 6.
Among the several drivers of inflammation in tumors, the inducible isoform of 
cyclooxygenases (COX), COX-2, plays a crucial role by ensuring a continuous supply of 
prostaglandin E2 (PGE2) to the tumors7. The other COX isoform, COX-1, is constitutively 
expressed in the body where it performs housekeeping functions8. In contrast to COX-1, 
COX-2 expression is short-lived9 and is upregulated in most tumors to meet up with the 
requirement for PGE2 in the rapidly proliferating cells7b. Both COX isoforms facilitate the 
conversion of arachidonic acid to prostaglandin H2, which is in turn transformed to 
prostaglandins, by specific synthases, as required by the cells7b, 10. Several COX inhibitors 
(Figure 2), also known as non-steroidal anti-inflammatory drugs (NSAIDs), have been 
approved by the FDA for managing inflammation associated with pains and fever.
Due to high expression of COX-2 in most tumors, it has been suggested that NSAIDs could 
someday find applications in the prevention and/or cure of some cancers, especially colon 
and prostate cancer11. Several mechanisms of cytotoxicity of NSAIDs towards cancer cells 
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have been reported; most are believed to be independent of COX-2 inhibition. In androgen 
dependent prostate cancer cell line (LNCaP), celecoxib exerts its cytotoxic effect via 
induction of c-jun12 and EP2 signaling leading to suppression of androgen receptor (AR)13. 
Induction of apoptosis14, Wnt/beta-catenin pathway suppression15, cell cycle arrest16 and 
inhibition of angiogenesis17 are some of the other mechanisms through which NSAIDs exert 
their anticancer activity. In addition to being a possible therapeutic target, COX-2 
upregulation in tumors has been exploited for tumor imaging through the use of contrast 
agents containing COX-2-selective NSAIDs18.
Recently, there has been enormous interest in the development of dual-acting compounds 
comprising of an HDACi and another cytotoxic component19. In such compounds, one of 
the "warheads” is usually the surface recognition group (cap) of the HDACi (see 
pharmacophoric model in Figure 4a). While dual-acting compounds comprising NSAIDs 
and other agents exist20, none contain HDACi and NSAIDs combined as a single 
component. Moreover, results from in vitro studies suggest that enhanced cytotoxic effect 
could be achieved by combining NSAIDs and HDACi in cancer cell lines21. In this study, we 
designed and synthesized bifunctional compounds with HDAC and COX-2 inhibitory 
activities. These compounds are capable of harnessing the cytotoxic effects of HDAC 
inhibition, COX-2 inhibition, and perturbation of other non-COX dependent pathways. Our 
design has indomethacin or celecoxib as the cap, methylenes as linkers, and hydroxamate as 
the zinc binding group (ZBG) (Figure 4b–e). These compounds potently inhibited the 
HDAC isoforms tested and retained COX-2 inhibitory activity comparable to both celecoxib 
and indomethacin. The potent HDAC and COX-2 inhibitory activities of these conjugates 
are reflected in their growth inhibitory activities in MCF-7 (breast cancer), A549 (non-small 
cell lung cancer), HCT-116 (colon cancer), DU-145 (androgen independent prostate cancer) 
and LNCaP (androgen dependent prostate cancer) cell lines. They are also less toxic towards 
healthy cell (VERO) compared to vorinostat.
1. RESULTS AND DISCUSSION
1.1. Design rationale
The residues presented at the outer rim of HDAC enzymes form rugged landscapes designed 
to flexibly accommodate a diverse class of substrates. This may explain the tolerance of the 
HDAC outer rim for incorporation of various surface recognition groups into the design of 
structurally dissimilar HDACi. Taking this into consideration, we hypothesized that 
incorporation of celecoxib (a COX-2 selective inhibitor) and indomethacin (a non-selective 
inhibitor of COX isoforms) into the surface recognition cap group of an HDACi may result 
in dual-acting agents that inhibit both HDAC and COX-2. Such agents are likely to show 
enhanced tumor cell cytotoxicity and superior therapeutic index compared to the individual 
HDACi and COX-2 inhibitors.
To determine which site to modify on celecoxib, we analyzed the orientation of celecoxib in 
the COX-2 active site. We found that the sulfonamide (SO2NH2) and trifluoromethyl (CF3) 
moieties of celecoxib are projected towards different solvent exposed regions of the enzyme 
(Figure 3a–b). Based on this analysis, the sulfonamide and trifluoromethyl moieties could be 
suitable points for the attachment of HDAC-inhibiting pharmacophores. Modifications at 
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these two ends should minimally perturb the binding of celecoxib-based conjugates to the 
COX-2 active site, as shown in previous studies20b, 22. Because of the relaxed specificity for 
hydrophobic groups at the HDAC outer rims, the celecoxib aromatic moiety of the resulting 
dual-acting agents is expected to be accommodated as a surface recognition group when 
bound to HDAC enzymes. To test this deduction, we designed and synthesized celecoxib-
HDACi conjugates in which: i) HDACi template is attached to the sulfonamide (series 1, 
Figure 4) ii), the “CF3” is replaced by HDACi template (series 2, Figure 4) and iii) the 
sulfonamide is replaced with a methyl sulfone (SO2Me) and “CF3” is replaced by HDACi 
template (series 3, Figure 4).
Similarly for indomethacin, the carboxylic acid moiety is projected towards the solvent 
exposed region of COX-2 (Figure 3c). Modification of this moiety is known to convert 
indomethacin from a non-selective COX inhibitor to a COX-2 selective inhibitor23. This 
prompted us to design and synthesize indomethacin-HDACi conjugates in which the HDACi 
template is attached to the carboxylic acid end (series 4, Figure 4). Further modifications of 
indomethacin yielded conjugates in which the chlorobenzoyl is replaced by HDACi 
template, and carboxylic acid is either esterified or left unmodified (series 5, Figure 4).
In all the NSAID-HDACi conjugates, linker lengths were restricted to five, six and seven 
methylenes separating the ZBG from the cap groups, in accordance with a previous study in 
our lab showing these lengths to be optimal for HDAC inhibition24.
1.2. Chemistry
The sulfonyl chloride 1, a vital intermediate required in the synthesis of sulfonamide-
modified celecoxib-HDACi conjugates, was made according to a previously reported 
protocol25. The desired conjugates 2a–c were thereafter made by displacement of chloride 
from compound 1 with trityl-protected primary amine having methylene linkers of 
appropriate lengths, followed by removal of trityl-protection with TFA (scheme 1).
To access the series 2 conjugates, the 1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-
carboxylic acid intermediate 5 was made by hydrolysis of ethyl 1-(4-sulfamoylphenyl)-5-(p-
tolyl)-1H-pyrazole-3-carboxylate 4, whose synthesis had been previously reported26, using 
lithium hydroxide (scheme 2). Subsequent coupling of compound 5 to trityl-protected 
primary amine having methylene linkers of appropriate lengths followed by trityl 
deprotection furnished the desired celecoxib-HDACi conjugates 7a–c in decent yields. 
Likewise, the methyl sulfone analog 8 (series 3) was made from 6 using the same chemistry.
The first series of indomethacin-based COXi-HDACi conjugates (series 4) were made from 
the NHS-activated indomethacin intermediate 10, which was obtained by reacting 
indomethacin with disuccinimidyl carbonate (scheme 3). Displacement of NHS by trityl-
protected primary amine having methylene linkers of appropriate lengths and subsequent 
trityl removal furnished conjugates 11a–c in good yields.
The esterified indole 12 required to synthesize the second series of indomethacin-HDACi 
conjugates was obtained by hydrolysis of indomethacin using NaOH followed by 
esterification using TMSCl in MeOH. Reaction of 12 with 4-ethynylbenzyl mesylate 13 in 
Raji et al. Page 4
Bioorg Med Chem. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the presence of sodium hydride, gave the N-alkylated alkyne intermediate 14 (scheme 4). 
Via Cu (I) catalyzed azide-alkyne cyclo-addition reaction between alkyne 14 and trityl-
protected azide having methylene linkers of appropriate lengths 15a–c, trityl-protected 
precursors to the final compounds 16 and 17a–c were made. Ester hydrolysis with lithium 
hydroxide followed by trityl deprotection using TFA furnished the NSAID-HDACi 
conjugate 16 while methyl ester compounds 17a–c were obtained by trityl deprotection of 
precursors to the final compounds (scheme 4).
1.3. HDAC isoforms inhibition screening
We screened all of the synthesized dual-acting COXi-HDACi compounds against all class I 
HDACs (HDACs 1–3 and HDAC 8) and HDAC6 (class IIB HDAC). These conjugates 
potently inhibited all the HDAC isoforms screened. A closer look at the enzyme inhibitory 
activities reveals a linker length dependency which generally favors longer methylene linkers 
with few key exceptions (Table 1). Across all the five HDAC isoforms tested, these 
conjugates showed the strongest inhibitory effect towards HDAC 6, with IC50 as low as 5 
nM for 17c. Among the celecoxib-based series (series 1–2), compounds 7a–c (series 2) 
showed more potency towards HDACs 1–3 compared to those of series 1 with the same 
linker lengths. This may be due to more favorable interaction of the 3’-amide and the free 
sulfonamide group, at the surface recognition group of conjugates, with potential H-bond 
donor/acceptor residues at the outer rim of the enzyme. In addition to the strong inhibitory 
effects towards HDAC 6 seen within the series 1 conjugates (compounds 2a–c), 2b also 
strongly inhibited HDACs 3 and 8, while 2c showed preference for HDAC 3 compared to 2a 
which has a strong inhibitory effect against HDAC 8. The only member of series 3 
conjugates, compound 8, is slightly more potent than compound 7b, the corresponding 
conjugate in series 2 with the same linker length.
In the indomethacin-based series, conjugates with triazolyl connecting the linker to the head 
group, compounds 17a–c (series 5), show greater inhibition of HDACs 1–3 and HDAC 6, 
compared to the amide-linked conjugates compounds 11a–c (series 4). Compounds 11a–c 
are equipotent towards HDAC 6, while they show varying activities towards other HDAC 
isoforms. It is noteworthy to point out that compound 16 and its methyl ester analog 17b 
show similar activity in all the HDAC isoforms screened, suggesting that modifying the 
carboxylic acid group in the series 5 conjugates does not result in loss of enzyme inhibitory 
activity. The remaining members of this series, 17a and 17c, have vastly varied anti-HDAC 
activities. Compound 17a is moderately active against HDACs 3 and 8 with little activity 
against HDACs 1, 2 and 6. Conversely, 17c is broadly active against all HDAC isoforms 
tested and it is the most potent HDAC 6 inhibitor among the dual-acting COXi-HDACi 
compounds herein disclosed.
1.4. Molecular docking analysis
To gain an insight into the specific interactions that may exist between our compounds and 
HDACs, which may explain the pattern of the observed HDAC inhibition, we docked all the 
compounds against HDAC 6. In all the series, we observed zinc chelation, typical of all 
hydroxamate-based HDACi, while the COX-binding moieties sit at surface of the enzyme 
(supporting information, Figure S1).
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In all the celecoxib-based conjugates (series 1–3), the “para tolyl” group makes a stabilizing 
pi-stacking interaction with PHE 680 residue at the surface of the enzyme. We observed that 
compound 2a, analog with the shortest linker among the series 1 compounds, had the phenyl 
at the headgroup and the linker pushed further down the active site to maximize chelation 
with Zn at the bottom of the active site (supporting information, Figure S1(i)). This slightly 
offset the pi-stacking interaction with PHE 680 at the surface of the enzyme, and may 
explain the slightly weaker activity against HDAC 6 compared to 2b and 2c. Compound 7b 
had a slightly different orientation at the surface of the enzyme, with its “para tolyl” group 
and “phenyl sulfonamide groups flipped, but still maintained pi-stacking interaction with 
PHE 680 and Zn chelation shown by compounds 7a, 7c and 8 (supporting information, 
Figure S1(iii)).
Among the indomethacin-based compounds, the series 4 conjugates, 11a–c, adopt a similar 
binding pose within the HDAC 6 active site, except for 11c (supporting information, Figure 
S1(v)). Despite this, compounds 11a–c have similar inhibitory effects on HDAC 6 (Table 1). 
All the series 5 conjugates, on the other hand, elicit a completely different interaction at the 
surface of the enzyme ((supporting information, Figure S1(vii)).
We also docked the conjugates against COX-2 to confirm that the structural modifications 
made on celecoxib and indomethacin do not appreciably compromise their interactions with 
COX-2. The selectivity of celecoxib towards COX-2 is attributed to its sulfonamide group 
forming four polar contacts (two H-bonding and two salt bridges) with His75, Arg499, 
Leu338 and Ser339 of COX-2, while the “para tolyl” group is projected towards the 
hydrophobic region in the active site27. Docking output of celecoxib-based series (series 1–
3) show that the conjugates overlay perfectly with celecoxib in the COX-2 active site with 
the HDACi moiety projected towards the solvent exposed region. Among the series 1 
conjugates, the “para tolyl” group is twisted perpendicularly to the plane of the “para tolyl” 
group of celecoxib (Figure 4 (i)), perhaps, to compensate for the modification at the 
sulfonamide end. The series 2 conjugates on the other hand, align perfectly with celecoxib in 
the COX-2 active site, with the appended HDACi template projecting towards the solvent 
exposed region (Figure 4 (ii)). All the conjugates bind COX-2 similarly, irrespective of the 
length of the appended HDACi template.
A similar observation was seen with the indomethacin-based series 4 conjugates, wherein all 
the conjugates align with indomethacin, except for compound 11c, with the HDACi 
appendage projected towards a pocket at the surface of the enzyme (Figures 4 (iii) and (iv)). 
We believe the misalignment of compound 11c, relative to indomethacin and other 
conjugates, is due to the length of the HDACi appendage. In order for the HDACi appendage 
to fit the pocket at the enzyme’s surface, there has to be a distortion in the binding mode 
within the active site leading to the misalignment (Figure 4 (iii)). The Series 5 conjugates 
present a different binding mode, with the methyl ester group projected towards the 
hydrophobic region occupied by the chlorobenzoyl group of indomethacin. Consistent with 
Supporting Information
Supplementary data associated with this article (1H NMR and 13C NMR spectral information) can be found online.
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previous observations in other series, all series 5 conjugates bind to the COX-2 active site in 
a similar fashion regardless of the length of the HDACi template.
1.5. COX inhibition study
We performed a preliminary screening (at 10µM) of all the bifunctional compounds against 
COX-1 and COX-2 enzymes using Cayman fluorescent inhibitor screening assay kit. Based 
on the preliminary screen, representative members from each series were selected for IC50 
determination in both COX isoforms (Table 2). In most cases, compounds within the same 
series showed similar percent inhibitory activities towards COX-1 and COX-2, validating 
our observation from docking which suggests that conjugates’ within the same series should 
have similar interactions with COX-2, independent of the length of the HDACi appendage.
The celecoxib based conjugate 2b retained selectivity towards COX-2 akin to celecoxib, 
though with reduced potency. Compound 7c was surprisingly less potent compared to 2b in 
the preliminary screen, despite having a near perfect alignment with celecoxib in the COX-2 
active site (Figure 4 (ii)) compared to the alignment of 2b (Figure 4 (i)). The only 
indomethacin-based compound evaluated for IC50, 11b, shows comparable level of potency 
towards COX-2 as indomethacin. Interestingly, the COX-2 selectivity of 11b rivals that of 
celecoxib, an FDA-approved COX-2-selective inhibitor. The COX-2-selectivity seen with 
compound 11b is consistent with observations in the literature on indomethacin modified at 
the carboxylic acid group23. Despite the drastic structural modifications to celecoxib and 
indomethacin templates which furnished compounds 8 and 17c respectively, these 
compounds still showed decent activity towards COX-2 (Table 2).
1.6. In vitro anticancer activity study
Encouraged by the impressive HDAC and COX inhibitory activities of our conjugates, we 
tested their growth inhibitory activities in a panel of cancer cell lines: breast (MCF-7), lung 
(A549), colon (HCT-116), androgen-dependent (LNCaP) and -independent (DU-145) 
prostate cancer cell lines. Healthy monkey kidney epithelial cells (VERO) were used as a 
positive control. Our choice of cancer cell lines was based on the expression profiles of 
different HDAC isoforms and COX-2 in the cell lines. All class I HDACs and HDAC 6 (a 
class IIb HDAC) play crucial roles in the survival of the chosen cancer cell lines2, 4. While 
COX-2 is ubiquitously expressed in the MCF-718a and A54930 cell lines, its expression is 
barely discernible in the HCT-116,22b a colon cancer cell line that is highly sensitive to 
HDAC inhibition through COX-2 independent mechanism(s).22c Prostate cancer cell lines 
(LNCaP and DU-145) were chosen to evaluate the selectivity of our compounds towards 
androgen dependent prostate cancer. COX-2-specific NSAIDs perturb androgen receptor 
(AR)-mediated functions which are critical for the survival of LNCaP12. Most of the 
conjugates show strong antiproliferative effects in all the cancer cell lines used in this study, 
and are less cytotoxic towards VERO compared to SAHA. More specifically, we observed 
the compounds to be considerably more potent towards androgen dependent prostate 
(LNCaP) and HCT-116 (with no COX-2 expression).
Among the conjugates based on celecoxib (series 1–3), compounds 2a–c show increasing 
activity with increase in methylene linker lengths in MCF-7 and A549 cell lines, consistent 
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with the trend observed in their HDACs 1–3 and 6 inhibition activities. A different trend is 
observed for these series of compounds in HCT-116 and LNCaP cell lines, as compound 2b 
potently inhibit the proliferation of both cell lines while 2c is less potent against HCT-116 
but equipotent as 2b against LNCaP (Table 3). Surprisingly, sulfonamide compounds 7a–c 
were barely cytotoxic across all cell lines (except for compound 7c), despite their impressive 
anti-HDAC activities. The inactivity of the sulfonamide-based compounds 7a–c may be due 
to lack of cell penetration to an appreciable extent. This deduction was supported by the fact 
that the methyl sulfone congener of inactive compound 7b, compound 8, showed anti-
proliferative activity that is consistent with its HDAC inhibitory activity and with exquisite 
selectivity toward AR-positive LNCaP and HCT-116 cells.
Most of the indomethacin-based conjugates potently inhibited the growth of all the cancer 
cell lines, with the effect more pronounced within the series 5 conjugates (17a–c). Notably, 
compound 17c showed IC50 comparable to vorinostat in A549 cell line and it is more 
cytotoxic towards LNCaP and HCT-116 in similar manner to the other active celecoxib-
based compounds. Considering their strong anti-HDAC and weak COX-2 inhibitory effect 
within the series 5 conjugates, mechanism of cytotoxicity in HCT-116 could be attributed, 
predominantly, to HDAC inhibition. The series 4 conjugates 11b and 11c showed reduced 
anticancer effect in all cell lines, except LNCaP against which they are still potently active. 
Compound 11a, the other member of this series, is poorly active or inactive against all cell 
lines tested. The cytotoxic effects of 11b and 11c towards LNCaP may be due to a combined 
effect of HDAC inhibition and inherent downregulation of AR associated with COX-2 
selective NSAIDs.
In healthy cells (VERO), these compounds are significantly less toxic when compared to 
vorinostat. Specifically, compound 8 is about ten-fold more selective towards prostate cancer 
cells (LNCaP) compared to VERO. Likewise, compounds 11b, 11c, 17b and 17c displayed 
varying level of selective cytotoxicity towards LNCaP compared to VERO.
1.7. Comparison of antiproliferative activity of bifunctional compounds and combination 
therapy of NSAIDs and HDACi
To investigate if there is an advantage in having bifunctional compounds compared to just a 
combination of the individual components (SAHA + Celecoxib; or SAHA + Indomethacin), 
we tested an equimolar concentration of the individual components, and compared their 
growth inhibitory activities to those of lead bifunctional compounds 2b and 11b in LNCaP, 
DU-145 and VERO. As shown in Figure 5a above, compound 2b, bifunctional compound 
derived from celecoxib template, is significantly more potent than a combination of 
celecoxib and SAHA in LNCaP, with no observable differences in DU-145 and VERO 
(Figures 5b and 5c respectively). This confirms compound 2b as a more selective and potent 
compound to treat AR positive prostate cancer. Indomethacin derived compound 11b on the 
other hand, while equipotent to a combination of indomethacin and SAHA in both LNCaP 
and DU-147 (Figures 5a and 5b respectively), is significantly less toxic to healthy cells, 
VERO (Figure 5c). Hence, a hybrid of indomethacin and HDACi, 11b, has a superior 
therapeutic index when compared to a combination of equimolar concentrations of 
indomethacin and SAHA.
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Overall, compound 2b is more potent (Figure 5a) and selective towards LNCaP (Figure S3a, 
supporting information) compared to compound 11b and a combination of SAHA and the 
respective NSAID, while compound 11b has the highest in vitro selective toxicity index.
1.8. Intracellular target validation
Using western blot, we probed for evidence of intracellular HDAC inhibition among our 
compounds in LNCaP. Inhibition of HDAC 6 is known to result in accumulation of 
acetylated tubulin in the cytosol31. In this experiment, we chose compound 2b as a 
representative of all celecoxib-based conjugates (series 1–3), while compounds 11b and 17b 
were selected as representatives of series 4 and 5 conjugates respectively. SAHA was used as 
the positive control. As expected, all the tested compounds showed accumulation of 
acetylated tubulin in a concentration dependent manner (Figure 6, panel 1). Compound 17b, 
a highly potent HDAC 6 inhibitor (IC50 ≈ 10 nM), showed about the same level of acetyl 
tubulin at 1.5 µM (Figure 6, panel 1, lane 7) as SAHA at 10 µM (Figure 6, panel 1, lane 2). 
A similar trend was observed with histone H4 acetylation (a marker of class 1 HDAC 
inhibition) (see supporting information Figure S2).
According to Yamaguchi et al32, HDAC inhibition causes downregulation of PMA-induced 
COX-2 expression in cancer cell lines. A similar observation was obtained when we treated 
LNCaP cells with SAHA at 10 µM (Figure 6, panel 3, lane 2). Our observation, following 
treatment with compounds 11b and 17b, was contrary to this, as we saw sustained COX-2 
expression levels at the tested concentrations (Figure 6, panel 3, lanes 5–7). Compound 2b, 
on the other hand, showed COX-2 downregulation at low concentration (2 µM) and a slight 
upregulation a higher concentration (10 µM) (Figure 6, panel 3, lanes 3–4). The implication 
of this may be that the cytotoxic effect of these compounds in LNCaP may be less dependent 
on their effects on COX-2 expression. This is not without precedence, as other selective 
COX-2 1 2 3 4 5 6 7 8 9 Acetyl tubulin AR COX-2 Actin inhibitors are known to induce 
apoptosis independent of COX-2 expression14, 33. However, the sustained COX-2 expression 
level observed with our compounds, clearly distinguishes them from SAHA. This may prove 
to be advantageous in in vivo experiments with prostate cancer, as the COX-2 binding 
component of our compounds may confer selective localization in the tumor. AR 
upregulation is critical to the survival of LNCaP34. In our study with LNCaP, SAHA 
significantly suppressed AR expression at 10 µM (Figure 6, panel 2, lane 2), consistent with 
the literature35. Compounds 2b showed a similar effect in a concentration dependent manner 
(Figure 6, panel 2, lanes 3–4). Quite unexpectedly, AR downregulation was much weaker for 
compound 11b (Figure 6, panel 2, lanes 5–6), while compound 17b showed no noticeable 
effect at the single concentration tested (Figure 6, panel 2, lane 7). Both celecoxib and 
indomethacin showed no effects on AR regulation at 10 µM (Figure 6, panel 2, lanes 8 and 
9). All together, these observations suggest that our compounds might be perturbing distinct 
pathways to elicit antiproliferative activities against LNCaP cells. Compound 2b acts more 
like a typical HDACi via induction protein acetylation and downregulation of AR. In 
contrast, 11b and 17b are atypical as they have no effect on AR expression. They most likely 
derived their potent anti-proliferative effect on LNCaP cells through a combination of 
COX-2-facilitated cell uptake, HDAC inhibition and perturbation of other pathways unique 
to prostate cancer.
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1.9. Effect of bifunctional compounds on PGE2 expression
One of the consequences on intracellular COX inhibition is decreased production of 
prostaglandin E2 (PGE2)36. To confirm that the strong COX-2 inhibitory effects of our 
compounds is maintained in cells, we treated HeLa cells with compounds 2b, 11b, celecoxib 
and indomethacin for 24 hours then measured the level of PGE2 produced in the cell culture 
supernatant. HeLa cell line was chosen for this study because it has been previously used for 
a similar study36 (see Table S1 supporting information for the IC50 of these compounds in 
HeLa cells). As shown in Figure 7, both compounds 2b and 11b significantly inhibited 
PGE2 production, confirming that these NSAID-HDACi conjugates possess intracellular 
COX-2 inhibitory activities as well.
1.10. Effect of lead compound on cell cycle progression
To determine if the potent cell proliferation inhibition activities of these compounds result 
from their perturbation of the cell cycle pattern, we evaluated the effect of compounds 2a, 8, 
11b and 17b on LNCaP cell cycle progression using SAHA, celecoxib and indomethacin as 
controls. We observed that the effect of celecoxib and indomethacin (both at 40 µM) was not 
significantly different from the DMSO control. SAHA at 2.5 µM induced a G0/G1 phase 
arrest as reported previously in the literature35 (Figure 8). Compound 8, at 2.5 µM, displayed 
a similar G0/G1 phase arrest as SAHA. This is not unexpected, since 8 has a broad HDAC 
inhibition activity and only weak inhibitory effect against COX- 2 (Table 2). Compared to 8, 
compounds 2a, 11b and 17b, have a distinct effect on cell cycle progression. At 2.5 µM, 
they induced a significant S phase arrest. This may be as a result of their combined HDAC 
and COX-2 inhibitory effects.
1.11. Bifunctional compounds suppress NTHi-induced NF-κB activation
NF-κB activation drives inflammation and tumorigenesis in cancer. The two pathways 
involved in NF-κB activation (canonical and non-canonical pathways) are initiated by pro-
inflammatory cytokines such as TNFα and interleukins37. We recently reported that HDACi 
downregulate inflammatory cytokines release and NF-κB activation38. Likewise, there is 
evidence for non-COX inhibition dependent downregulation of NF-κB activation by 
NSAIDs39. In view of these, we investigated the ability of our bifunctional compounds to 
suppress NF-κB activation in BEAS-2B cells treated with nontypeable Haemophilus 
influenzae (NTHi) using NF-κB luciferase assay. NTHi is a Gram-negative bacterium which 
causes infection in the human respiratory tract. NF-κΒ is potently activated upon NTHi 
infection in human epithelial cells, and induces pro-inflammatory mediators such as IL-1β, 
IL-6 and TNF-α.
We screened representative NSAID-HDACi conjugates with potent HDAC inhibition 
activities and observed that compounds 8 and 17b suppressed NTHi-induced NF-κB 
activation in BEAS-2B cells almost to the same extent as SAHA (Figure 9). In this assay, 
compound 2c, celecoxib and indomethacin also showed some level of suppression of NF-κB 
(Figure S5, supporting information). Considering the fact that compounds 8 and 17b have 
moderate COX and strong HDAC inhibitory activities, their ability to downregulate NF-κB 
activation is likely a consequence of their HDAC inhibitory capability. In summary, these 
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results demonstrate that representative NSAID-HDACi conjugates could suppress 
inflammation due to their ability to inhibit NF-κB activation.
3. Conclusion
The clinical success of HDACi as a single agent in the treatment of solid tumors continues to 
remain elusive. Approaches currently exploited to make this achievable include: i) using a 
non-hydroxamate ZBG40, ii) having a targeting group attached to the surface recognition 
group19a, iii) making dual acting conjugates comprising a cytotoxic component and HDACi 
template19a, and iv) using a prodrug approach41. Herein, we described compounds that 
potently and selectively inhibit COX-2 while also maintaining strong anti-HDAC activity. In 
addition to exploiting the anticancer effects of the two enzyme inhibitory templates in our 
design, we anticipate that these compounds may show selective localization in tumors as 
seen with other conjugates comprising a COX-2-selective inhibitor and a 
fluorophore18a, 18c, 22b, 42. This approach has led to the discovery of compounds with strong 
growth inhibitory activities in various cancer cell lines with a strong preference for 
androgen-dependent prostate cancer cell line (LNCaP). While the selectivity towards LNCaP 
is not fully understood, we postulate that it could be a consequence of the effect of COX-2 
and HDAC inhibition on AR functions. Previous studies on the effect of NSAIDs on AR in 
LNCaP suggest that COX-2 inhibition led to induction of the transcription factor c-jun, 
which in turn results in inhibition of AR activity12. HDAC inhibition on the other hand, 
leads to decreased AR expression35.
Compared to SAHA, our lead compounds (2b, 2c, 8, 11b, 17b and 17c) showed superior in 
vitro therapeutic index in all cancer cell lines relative to the positive control VERO. 
Compounds 8 and 11b are particularly impressive in this regard, with about a ten-fold 
increase in selective cytotoxicity towards LNCaP relative to VERO. Lastly, we observed 
significant differences in the perturbation of cell cycle progression by compounds 2b, 11b 
and 17b, compared to SAHA, celecoxib and indomethacin that may be due to their 
combined effects on COX-2 and HDAC.
4. Experimental
4.1 Materials and methods
All commercially available starting materials were used without further purification. 
Indomethacin was purchased from TCI America (OR, USA). Reaction solvents were either 
high performance liquid chromatography (HPLC) grade or American Chemical Society 
(ACS) grade and used without further purification. Analtech silica gel plates (60 F254) were 
used for analytical TLC, and Analtech preparative TLC plates (UV 254, 2000 µm) were used 
for purification. UV light was used to examine the spots. 200–400 mesh silica gel was used 
in column chromatography. For NMR spectra, Varian-Gemini 400 MHz or Bruker 500 MHz 
magnetic resonance spectrometer was used. 1H NMR spectra were recorded in parts per 
million (ppm) relative to the peak of CDCl3, (7.26 ppm), CD3OD (3.31 ppm), or DMSO-d6 
(2.49 ppm). 13C spectra were recorded relative to the central peak of the CDCl3 triplet (77.0 
ppm), CD3OD (49.0 ppm), or the DMSO-d6 septet (39.7 ppm) and were recorded with 
complete heterodecoupling. Multiplicities are described using the abbreviations: s, singlet; d, 
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doublet, t, triplet; q, quartet; m, multiplet. High-resolution mass spectra were recorded at the 
Georgia Institute of Technology mass spectrometry facility in Atlanta. HPLC was used to 
establish the purity of the compounds to be >95%. The HPLC analyses were done on a 
Beckman Coulter instrument with a Phenomenex RP C-18 column (250 mm × 4.6 mm), 
using 0.1% TFA in water (solvent A) and 0.1% TFA in acetonitrile (solvent B), starting with 
70% B for 5 min, then a gradient decrease of 70−10% of B over 20 min. The flow rate was 
1.0 mL/min and detection was at 280 nm. 4-Ethynyl-benzyl methylsulfonate 13, trityl-
protected azide and amine linkers were made as previously described43.
Du-145, LNCaP, Vero and A549 cell lines were purchased from ATCC (Manassas, VA), 
while MCF-7 and HCT-116 were generous a gifts from Dr. Al Merrill’s and Dr. Julia 
Kubanek’s laboratories respectively, at Georgia Institute of technology, Atlanta, GA. Cell 
cultures were maintained in an incubator at 37°C under a 5% CO2 atmosphere. Mouse 
antiacetylated α- tubulin antibody was obtained from Invitrogen (Life Technologies, Grand 
Island, NY, USA), rabbit antiactin, and rabbit antitubulin α antibodies were purchased from 
Sigma-Aldrich (St. Louis, MO, USA), AR antibody was purchased from Cell Signaling, 
while COX-2 antibody was purchased from Cayman chemicals. Secondary antibodies, goat 
antirabbit conjugated to IRDye680, and goat antimouse conjugated to IRDye800 were 
purchased from LI-COR Biosciences (Lincoln, NE, USA). The CellTiter 96 Aqueous One 
Solution Cell Proliferation assay (MTS) kit was purchased from Promega (Madison, WI, 
USA).
4.1.1 N-Hydroxy-6-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) phenyl) 
sulfonamido) hexanamide (2a)—Triethylamine (0.02 mL, 0.175 mmol) was added to a 
solution of trityl-protected 6-aminohexanehydroxamic acid (0.05 g, 0.13 mmol) in CHCl3 
(10 mL) and left to stir under argon for 5 minutes. Thereafter, a solution of 4-(5-(p-tolyl)-3-
(trifluoromethyl)-1H-pyrazol-1-yl) benzenesulfonyl chloride (0.05 g, 0.13 mmol) in 
anhydrous CHCl3 (5 mL) was added and the reaction left to stir overnight. Reaction was 
quenched with water (20 mL) and extracted with DCM (20 mL) three times. Combined 
organic layers were dried over anhydrous sodium sulfate and concentrated in vacuo. Residue 
was purified with prep TLC to give 6-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) 
phenyl)sulfonamido)-N-(trityloxy)hexanamide an off-white solid (0.08 g, 0.10 mmol) which 
was immediately used for the next reaction without characterization.
To a solution of 6-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl) 
phenyl)sulfonamido)-N-(trityloxy)hexanamide (0.08 g, 0.10 mmol) in anhydrous DCM (10 
mL) were added TFA (1.5 mL) and TIPS (0.75 mL). Reaction was stirred at room 
temperature for one hour. Solvent was evaporated and the resulting residue purified by prep 
TLC using DCM:Acetone:AcOH (2:1:0.1) to give 2a as an off-white solid (0.03 g, 60%). 
HPLC retention time 16.22 minutes. 1H NMR (400 MHz, CD3OD) δ 7.90 (d, J = 8.5 Hz, 
2H), 7.54 (d, J = 8.5 Hz, 2H), 7.21 (q, J = 8.2 Hz, 4H), 6.94 (s, 1H), 2.90 (t, J = 6.8 Hz, 2H), 
2.38 (s, 3H), 2.09 (m, 2H), 1.60 (m, 2H), 1.54 – 1.45 (m, 2H), 1.34 (m, 2H).13C NMR (101 
MHz, CD3OD) δ 145.7, 143.5, 142.6, 142.1, 140.7, 139.8, 129.2, 128.6, 127.6, 125.7, 124.4, 
122.3, 105.6, 42.5, 28.9, 25.8, 25.6, 24.8, 19.9. HRMS (ESI) [M + H]+ calculated for 
[C23H26O4N4F3S]+ was 511.1621, found 511.1608.
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4.1.2 N-Hydroxy-7-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-
yl)phenyl)sulfonamido) heptanamide (2b)—Trityl-protected 7-
aminoheptanehydroxamic acid (0.05 g, 0.14 mmol) was reacted with 4-(5-(p-tolyl)-3-
(trifluoromethyl)-1H-pyrazol-1-yl) benzenesulfonyl chloride (0.05g, 0.13mmol) in 
anhydrous CHCl3 (5 mL) containing TEA (0.03 mL, 1.87 mmol) similar to compound 2a 
above, to give 7-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonamido)-
N-(trityloxy) hexanamide as an off-white solid (0.08 g, 0.11 mmol) which was used for the 
next reaction (trityl deprotection) without characterization.
Trityl deprotection was done as described for 2a in a DCM (10 mL) solution containing TFA 
(1.5 mL) and TIPS (0.75 mL). Purification was by prep TLC using DCM:Acetone:AcOH 
(2:1:0.1) to give 2b as an off-white solid (0.05 g, 92%). HPLC retention time 16.22 
minutes. 1H NMR (500 MHz, CD3OD) δ 7.89 (d, J = 8.1 Hz, 2H), 7.53 (d, J = 8.1 Hz, 2H), 
7.21 (dd, J = 18.5, 7.7 Hz, 4H), 6.93 (s, 1H), 2.89 (t, J = 6.5 Hz, 2H), 2.37 (s, 3H), 2.10 (s, 
2H), 1.60 (s, 2H), 1.47 (s, 2H), 1.32 (s, 5H). 13C NMR (126 MHz, MeOD) δ 145.7, 143.7, 
143.3, 142.2, 140.8, 139.7, 129.1, 128.7, 127.7, 125.8, 122.4, 120.2, 105.5, 42.6, 29.1, 28.2, 
27.8, 25.9, 25.2, 19.9. HRMS (ESI) [M + H]+ calculated for [C24H28O4N4F3S]+ was 
525.1778, found 525.1771.
4.1.3 N-Hydroxy-7-((4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-
yl)phenyl)sulfonamido) octanamide (2c)—Trityl-protected 8-aminooctanehydroxamic 
acid (0.06 g, 0.14 mmol) was reacted with 4-(5-(p-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-
yl) benzenesulfonyl chloride (0.05 g, 0.13 mmol) in anhydrous CHCl3 (5 mL) containing 
TEA (0.03 mL, 1.87 mmol) similar to compound 2a above, to give 8-((4-(5-(p-tolyl)-3-
(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)sulfonamido)-N-(trityloxy) octanamide an off-
white solid (0.09 g, 0.11mmol) which was used for the next reaction (trityl deprotection) 
without characterization.
Trityl deprotection was done as described for 2a in a DCM (10 mL) solution containing TFA 
(1.5 mL) and TIPS (0.75 mL). Purification was by prep TLC using DCM:Acetone:AcOH 
(2:1:0.1) to give 2c as an off-white solid (0.04 g, 71%). HPLC retention time 16.82 
minutes. 1H NMR (400 MHz, CD3OD) δ 7.86 (d, J = 7.3 Hz, 2H), 7.50 (d, J = 7.6 Hz, 2H), 
7.17 (dd, J = 14.9, 8.0 Hz, 4H), 6.91 (s, 1H), 2.85 (s, 2H), 2.34 (s, 3H), 1.58 (m, 2H), 1.43 
(m, 2H), 1.26 (m, J = 14.1 Hz, 8H).13C NMR (101 MHz, cd3od) δ 145.7, 143.4, 143.1, 
142.1, 140.7, 139.6, 129.2, 128.6, 127.6, 125.7, 122.5, 119.9, 105.5, 42.6, 29.1, 28.5, 28.4, 
26.2, 25.7, 19.9. HRMS (ESI) [M + H]+ calculated for [C25H30O4N4F3S]+ was 539.1934, 
found 539.1928.
4.1.4 1-(4-Sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylic acid (5)—Ethyl 
1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylate (1.33 g, 3.31 mmol) was 
dissolved in THF (30 mL) and LiOH.H2O (0.21 g, 4.97 mmol) was added followed by 6 mL 
of H2O. The reaction was left to stir at room temperature overnight. THF was evaporated off 
and product was precipitated off the resulting solution with 1N HCl. Precipitate was filtered 
and washed severally with H2O to give (5) as a white solid (1.14 g, 96%). 1H NMR (400 
MHz, DMSO-d6) δ 13.15 (s, 1H), 7.91 (d, J = 8.6 Hz, 2H), 7.56 (d, J = 8.8 Hz, 4H), 7.23 (q, 
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J = 8.2 Hz, 4H), 7.09 (s, 1H), 2.34 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 163.9, 146.2, 
145.6, 144.5, 142.6, 139.7, 130.4, 129.7, 127.8, 127.0, 126.8, 111.1, 21.8.
4.1.5 1-(4-(Methylsulfonyl)phenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylic acid (6)
—Ethyl 1-(4-(methylsulfonyl)phenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxylate (0.42 g, 1.08 
mmol) was reacted with LiOH.H2O (0.09 g, 2.16 mmol) following the same procedure for 5 
above to give 6 as a white solid (0.38 g, 100%). 1H NMR (400 MHz, DMSO-d6) δ 8.03 (d, 
J = 8.7 Hz, 2H), 7.61 (d, J = 8.6 Hz, 2H), 7.26 – 7.17 (m, 4H), 7.09 (s, 1H), 3.31 (s, 3H), 
2.33 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 163.4, 145.8, 145.1, 143.5, 140.6, 139.3, 
129.9, 129.2, 128.7, 126.5, 126.3, 110.8, 43.7, 21.2.
4.1.6 N-(6-(Hydroxyamino)-6-oxohexyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-
pyrazole-3-carboxamide (7a)—EDCI (0.03 g, 0.17 mmol) and HOBT (0.02 g, 0.17 
mmol) were added to a solution of 1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-
carboxylic acid (5) (0.05 g, 0.14mmol) in CHCl3 (10 mL). The mixture was stirred at room 
temperature for 30 minutes after which trityl-protected 6-aminohexanehydroxamic acid 
(0.06 g, 0.154 mmol) was added, then left to stir overnight. The reaction was quenched with 
NaHCO3 (20 mL) and extracted three times with DCM (20 mL). Combined organic layer 
was dried over anhydrous Na2SO4 and concentrated in vacuo. Crude product was purified by 
prep TLC using DCM:Acetone:AcOH (5:1:0.1) to give N-(6-oxo-6-
(trityloxy)amino)hexyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxamide, 
which was used for the next reaction (trityl deprotection) without characterization.
To a solution of N-(6-oxo-6-(trityloxy)amino)hexyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-
pyrazole-3-carboxamide (0.06 g, 0.08 mmol) in anhydrous DCM (10 mL), TFA (1.5 mL) 
and TIPS (0.75 mL) were added. Reaction was stirred at room temperature for one hour. 
Solvent was evaporated and the resulting residue purified by prep TLC using 
DCM:MeOH:AcOH (10:1:0.1) to give 7a as an off white solid (0.03 g, 50%). HPLC 
retention time 9.47 minutes 1H NMR (500 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.09 (d, J = 8.1 
Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.42 (dd, J = 18.1, 7.9 Hz, 4H), 7.20 (s, 1H), 5.98 (s, 1H), 
3.47 (d, J = 5.5 Hz, 2H), 2.54 (s, 3H), 1.73 (m, J = 6.7 Hz, 3H), 1.47 (m, J = 14.0 Hz, 
3H). 13C NMR (126 MHz, DMSO-d6) δ 161.6, 148.7, 145.3, 144.3, 142.6, 139.3, 130.2, 
129.5, 127.4, 126.6, 108.8, 55.8, 30.1, 29.8, 27.5, 26.8, 25.7, 25.1, 21.7. HRMS (ESI) [M + 
H]+ calculated for [C23H28 O5N5S]+ was 486.1806, found 486.1804.
4.1.7 N-(7-(Hydroxyamino)-7-oxoheptyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-
pyrazole-3-carboxamide (7b)—Trityl-protected 7-aminoheptanehydroxamic acid (0.08 
g, 0.16 mmol) was reacted with a solution of 1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-
pyrazole-3-carboxylic acid (5) (0.05 g, 0.14 mmol), HOBT (0.02 g, 0.17 mmol) and EDCI 
(0.03 g, 0.17 mmol) in CHCl3 (10 mL) similar to compound 7a above, to give N-(7-oxo-7-
((trityloxy)amino)heptyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxamide as 
an brown solid (0.08 g, 0.11 mmol) which was used for the next reaction (trityl deprotection) 
without characterization.
Trityl deprotection was done as described for 7a. Purification was by prep TLC using 
DCM:MeOH:AcOH (10:1:0.1) to give 7b as a brown solid (0.02 g, 36%). HPLC retention 
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time 10.13 minutes 1H NMR (500 MHz, DMSO-d6) δ 8.34 (s, 1H), 7.87 (d, J = 8.4 Hz, 
2H), 7.53 (d, J = 8.4 Hz, 2H), 7.20 (dd, J = 18.1, 8.1 Hz, 4H), 6.98 (s, 1H), 3.25 (d, J = 3.3 
Hz, 2H), 2.32 (s, 3H), 1.95 (m, 2H), 1.50 (m, 4H), 1.26 (m, J = 19.3 Hz, 4H). 13C NMR (126 
MHz, DMSO) δ 161.9, 149.1, 145.7, 144.5, 142.8, 139.7, 130.5, 129.7, 127.7, 127.3, 126.9, 
109.2, 39.6, 30.3, 29.5, 27.3, 26.3, 26.2, 21.9. HRMS (ESI) [M + H]+ calculated for 
[C24H30O5N5S]+ was 500.1962, found 500.1956.
4.1.8 N-(8-(Hydroxyamino)-8-oxooctyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-
pyrazole-3-carboxamide (7c)—Trityl-protected 8-aminooctanehydroxamic acid (0.06 g, 
0.15 mmol) was reacted with a solution of 1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-
carboxylic acid (5) (0.05 g, 0.14 mmol), HOBT (0.02 g, 0.17 mmol) and EDCI (0.03 g, 
0.17mmol) in CHCl3 (10 mL), as described for compound 7a above, to give N-(8-oxo-8-
((trityloxy)amino)octyl)-1-(4-sulfamoylphenyl)-5-(p-tolyl)-1H-pyrazole-3-carboxamide as 
an brown solid (0.08 g, 0.11 mmol) which was used for the next reaction (trityl deprotection) 
without characterization.
Trityl deprotection was done as described for 7a. Purification was by prep TLC using 
DCM:MeOH:AcOH (10:1:0.1) to give 7c as a brown solid (0.02 g, 36%). HPLC retention 
time 10.92 minutes. 1H NMR (500 MHz, DMSO-d6) δ 8.37 (s, 1H), 7.90 (d, J = 8.1 Hz, 
2H), 7.56 (d, J = 8.1 Hz, 2H), 7.23 (dd, J = 18.1, 7.9 Hz, 4H), 7.01 (s, 1H), 3.28 (s, 2H), 2.35 
(s, 3H), 1.97 (m, 2H), 1.54 (m, 4H), 1.29 (m, J = 21.0 Hz, 8H). 13C NMR (126 MHz, 
DMSO) δ 161.3, 148.5, 144.9, 143.8, 142.1, 139.1, 129.9, 129.1, 127.2, 126.7, 126.2, 108.4, 
35.3, 31.9, 29.6, 29.0, 28.2, 26.8, 21.3. HRMS (ESI) [M + H]+ calculated for 
[C25H32O5N5S]+ was 514.2119, found 514.2106.
4.1.9 N-(7-(Hydroxyamino)-7-oxoheptyl)-1-(4-(methylsulfonyl)phenyl)-5-(p-
tolyl)-1H-pyrazole-3-carboxamide (8)—Trityl-protected 7-aminoheptanehydroxamic 
acid (0.12 g, 0.31 mmol) was reacted with a solution of 1-(4-(methylsulfonyl)phenyl)-5-(p-
tolyl)-1H-pyrazole-3-carboxylic acid (6) (0.10 g, 0.28 mmol), HOBT (0.04 g, 0.31 mmol) 
and EDCI (0.06 g, 0.30 mmol) in CHCl3 (10 mL) as described for compound 7a above, to 
give 1-(4-(methylsulfonyl)phenyl)-N-(7-oxo-7-((trityloxy)amino)heptyl)-5-(p-tolyl)-1H-
pyrazole-3-carboxamide as an brown solid (0.08 g, 0.11 mmol) which was used for the next 
reaction (trityl deprotection) without characterization.
Trityl deprotection was done as described for 7a. Purification was by prep TLC using 
DCM:MeOH:AcOH (10:1:0.1) to give 8 as a brown solid (0.02 g, 36%). HPLC retention 
time 11.13 minutes. 1H NMR (400 MHz, dmso) δ 8.41 (s, 1H), 8.03 (d, J = 8.4 Hz, 2H), 
7.63 (d, J = 8.4 Hz, 2H), 7.24 (q, J = 8.3 Hz, 4H), 7.01 (s, 1H), 3.31 (s, 3H), 2.35 (s, 3H), 
2.04 (m, 2H), 1.93 (m, 2H), 1.54 (m, 4H), 1.31 (m, 4H). 13C NMR (101 MHz, DMSO-d6) δ 
156.2, 148.5, 144.9, 143.5, 140.4, 139.2, 129.9, 129.1, 128.5, 126.6, 126.3, 109.0, 105.0, 
43.8, 32.3, 29.6, 28.7, 26.6, 25.6, 21.3. HRMS (ESI) [M + H]+ calculated for 
[C25H31O5N4S]+ was 499.2010, found 499.2010.
4.1.10 NHS-activated indomethacin (10)—Disuccinimidyl carbonate (0.86 g, 3.35 
mmol) was added to a mixture of indomethacin (1.00 g, 2.79 mmol) and TEA (0.50 mL, 
3.35 mmol) in DCM (20 mL). The reaction was stirred at room temperature overnight. 
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Solvent was evaporated off and the residue purified by column chromatography using DCM: 
Acetone (10:1) to give 10 as a white solid (1.04 g, 82%). 1H NMR (400 MHz, CDCl3) δ 
7.68 – 7.63 (m, 2H), 7.49 – 7.43 (m, 2H), 6.97 (d, J = 2.5 Hz, 1H), 6.94 – 6.89 (m, 1H), 6.69 
(dd, J = 9.0, 2.5 Hz, 1H), 3.96 (s, 2H), 3.85 (s, 3H), 2.80 (s, 4H), 2.37 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 169.1, 168.6, 166.5, 156.4, 139.6, 136.6, 133.9, 131.6, 130.9, 130.2, 
129.3, 115.3, 112.8, 110.4, 100.9, 55.9, 27.4, 25.8, 13.7.
4.1.11 6-(2-(1-(4-Chlorobenzoyl)-5-hydroxy-2-methyl-1H-indol-3-yl)acetamido)-
N-hydroxyhexanamide (11a)—TEA (0.02 mL, 0.16 mmol) was added to a solution of 
NHS-activated indomethacin 10 (0.05 g, 0.11 mmol) and trityl-protected 7-
aminoheptanehydroxamic acid (0.05 g, 0.12 mmol) in DCM (10 mL). The reaction was left 
to stir at room temperature for 3 hours. The reaction was quenched with water (20 mL) and 
extracted three times with DCM (20 mL). Combined organic layer was dried over Na2SO4 
and concentrated in vacuo. Residue obtained was purified by prep TLC using DCM: 
Acetone (10:1) to give 6-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-
yl)acetamido)-N-(trityloxy)hexanamide (0.07 g, 81%) which was used for the next reaction 
(trityl deprotection) without characterization.
Trityl group deprotection was done by dissolving 6-(2-(1-(4-chlorobenzoyl)-5-methoxy-2-
methyl-1H-indol-3-yl)acetamido)-N-(trityloxy)hexanamide in anhydrous DCM (10 mL) 
after which 1.5 mL TFA and 0.5 mL TIPS were added and the reaction was left to stir for 2 
hours. Saturated NaHCO3 solution (40 mL) was added to the reaction and extracted three 
times with DCM (20 mL) after gas evolution had ceased. Combined organic layer was dried 
over Na2SO4 and concentrated in vacuo. Crude residue was purified by prep TLC using 
DCM:Acetone:AcOH (2:1:0.1) to give 11a as a light brown solid (0.07 g, 75%). HPLC 
retention time 12.82 minutes. 1H NMR (400 MHz, CD3OD) δ 7.72 (d, J = 8.4 Hz, 2H), 7.58 
(d, J = 8.4 Hz, 2H), 7.03 (d, J = 2.2 Hz, 1H), 6.95 (d, J = 9.0 Hz, 1H), 6.70 (dd, J = 9.0, 2.3 
Hz, 1H), 3.86 – 3.80 (m, 3H), 3.62 (s, 2H), 3.22 (t, J = 6.7 Hz, 2H), 2.34 (s, 3H), 2.08 (s, 
2H), 1.58 (d, J = 33.3 Hz, 4H), 1.32 (d, J = 9.7 Hz, 2H). 13C NMR (101 MHz, CD3OD) δ 
168.6, 164.9, 156.2, 138.7, 135.7, 134.3, 131.0, 130.7, 128.8, 114.5, 113.5, 111.1, 104.4, 
101.0, 54.8, 52.8, 39.1, 30.9, 28.6, 26.0, 24.9, 12.3. HRMS (ESI) [M + H]+ calculated for 
[C25H29O5N3Cl]+ was 486.1790, found 486.1782.
4.1.12 7-(2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetamido)-
N-hydroxyheptanamide (11b)—Reaction of NHS-activated indomethacin 10 (0.10 g, 
0.22 mmol) with trityl-protected 7-aminoheptanehydroxamic acid (0.10 g, 0.24 mmol) in 
DCM (10 mL) containing TEA (0.04 mL, 0.26 mmol), as described for 11a, gave 7-(2-(1-(4-
chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetamido)-N-(trityloxy)heptanamide 
(0.14 g, 87%). Trityl deprotection was achieved as described for 11a to give 11b as a light 
brown solid (0.14 g, 87%). HPLC retention time 13.25 minutes. 1H NMR (400 MHz, 
DMSO-d6) δ 10.40 (s, 1H), 8.77 (s, 1H), 8.09 (s, 1H), 7.70 (dd, J = 17.6, 8.5 Hz, 4H), 7.15 
(d, J = 2.3 Hz, 1H), 6.97 (d, J = 9.0 Hz, 1H), 6.74 (dd, J = 9.0, 2.4 Hz, 1H), 3.83 – 3.76 (m, 
3H), 3.52 (s, 2H), 3.40 (s, 1H), 3.07 (d, J = 5.9 Hz, 2H), 2.32 – 2.21 (m, 3H), 1.95 (t, J = 7.3 
Hz, 2H), 1.46 (dd, J = 18.5, 11.6 Hz, 4H), 1.25 (m, 4H). 13C NMR (101 MHz, DMSO-d6) δ 
169.7, 169.1, 168.3, 156.0, 138.0, 135.6, 134.8, 131.6, 131.2, 131.0, 130.7, 129.6, 114.9, 
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111.6, 102.4, 55.8, 49.9, 32.7, 31.6, 29.4, 28.9, 26.6, 25.7, 14.0. HRMS (ESI) [M + H]+ 
calculated for [C26H31O5N3Cl]+ was 500.1947, found 500.1935.
4.1.13 8-(2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetamido)-
N-hydroxyoctanamide (11c)—Reaction of NHS-activated indomethacin 10 (0.05 g, 0.11 
mmol) with trityl-protected 7-aminoheptanehydroxamic acid (0.05 g, 0.12mmol) in DCM 
(10 mL) containing TEA (0.02 mL, 0.16 mmol), as described for 11a, gave 8-(2-(1-(4-
chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetamido)-N-(trityloxy)octanamide 
(0.08 g, 91%). Trityl deprotection was achieved as described for 11a to give 11c as a light 
brown solid (0.02 g, 47%). HPLC retention time 13.95 minutes. 1H NMR (400 MHz, 
CD3OD) δ 7.69 (d, J = 8.1 Hz, 2H), 7.55 (d, J = 8.1 Hz, 2H), 7.00 (s, 1H), 6.92 (d, J = 8.9 
Hz, 1H), 6.67 (d, J = 8.7 Hz, 1H), 5.49 (s, 2H), 3.80 (s, 3H), 3.59 (s, 2H), 3.19 (d, J = 5.5 
Hz, 2H), 2.31 (s, 3H), 1.52 (m, J = 28.6 Hz, 4H), 1.26 (m, J = 14.7 Hz, 8H). 13C NMR (101 
MHz, CD3OD) δ 170.9, 169.2, 162.8, 158.5, 149.8, 147.4, 141.0, 138.0, 136.6, 133.2, 131.1, 
116.8, 115.7, 113.6, 103.3, 57.1, 55.7, 44.5, 43.8, 41.4, 33.4, 31.0, 30.8, 28.8, 14.5. HRMS 
(ESI) [M + H]+ calculated for [C27H33O5N3Cl]+ was 514.2103, found 514.2087.
4.1.15 Methyl 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetate (12)—Indomethacin 
(3.00 g, 8.39 mmol) was dissolved in 1M NaOH (200 mL) and left to stir overnight. The 
reaction was acidified with 1M HCl and the precipitate filtered off. Filtrate was then 
extracted three times with DCM (100 mL). Combined organic layer was dried over Na2SO4 
and concentrated in vacuo to give crude 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetic acid 
(1.12 g, 5.15 mmol). The crude intermediate was dissolved in MeOH (50 mL) and TMSCl 
(1.86 mL, 14.73 mmol) was added. The reaction mixture was left to stir at room temperature 
overnight. Water (50 mL) was added to quench the reaction and extracted three times with 
DCM (50 mL). Organic layer was combined, dried over Na2SO4 and concentrated in vacuo. 
Residue obtained was purified by column chromatography using CHCl3:EtOAc (10:1) to 
give 12 as a brown solid (0.99 g, 83%). 1H NMR (400 MHz, CDCl3) δ 7.92 (s, 1H), 7.07 (d, 
J = 8.7 Hz, 1H), 7.01 (d, J = 2.0 Hz, 1H), 6.81 – 6.75 (m, 1H), 3.87 (d, J = 1.1 Hz, 3H), 3.68 
(d, J = 1.0 Hz, 5H), 2.32 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 172.8, 154.1, 133.7, 130.2, 
129.0, 111.1, 110.8, 104.1, 100.4, 55.9, 51.9, 30.3, 11.7.
4.1.16 Methyl 2-(1-(4-ethynylbenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate 
(14)—A solution of methyl 2-(5-methoxy-2-methyl-1H-indol-3-yl)acetate (12) (0.10 g, 0.43 
mmol) and NaH (60% dispersion in mineral oil) (0.03 g, 0.64 mmol) in anhydrous THF (10 
mL) was cooled to 0°C and left to stir for 20 minutes. The reaction was brought to room 
temperature, after which 4-ethynylbenzyl methanesulfonate (0.11 g, 0.51 mmol) was added, 
and left to stir overnight. Reaction mixture was poured into sat. NH4Cl (10 mL) and 
extracted three times with DCM (15 mL). Combined organic layer was dried over Na2SO4 
and concentrated in vacuo. Purification was by prep TLC using CHCl3:Ether (20:1) to give 
14 as a yellow solid (0.05g, 31%). 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.0 Hz, 2H), 
7.15 – 7.10 (m, 2H), 6.85 (d, J = 8.0 Hz, 2H), 6.80– 6.78 (m, 1H), 5.36 (s, 2H), 3.87 (s, 3H), 
3.73 (s, 2H), 3.69 (s, 3H), 3.08 (s, 1H), 2.31 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 172.8, 
154.1, 138.1, 135.0, 133.7, 130.2, 129.0, 128.0, 125.0, 121.6, 111.1, 110.8, 104.1, 100.4, 
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83.4, 55.9, 51.9, 46.8, 30.3, 11.7. HRMS (ESI) [M + H]+ calculated for [C22H21NO3]+ was 
347.1521, found 347.1529.
4.1.17 2-(1-(4-(1-(7-(Hydroxyamino)-7-oxoheptyl)-1H-1,2,3-triazol-4-yl)benzyl)-5-
methoxy-2-methyl-1H-indol-3-yl)acetic acid (16)—Methyl 2-(1-(4-ethynylbenzyl)-5-
methoxy-2-methyl-1H-indol-3-yl)acetate (14) (0.074 g, 0.21 mmol), trityl-protected 7-
azidoheptanehydroxamic acid (0.11 g, 0.26 mmol) and DIPEA (0.07 mL, 0.43 mmol) were 
dissolved in anhydrous THF (10 mL) and purged for 10 minutes at room temperature while 
stirring. CuI (0.02 g, 0.11 mmol) was then added with purging continued for another 20 
minutes. The reaction was left to stir overnight. Reaction was quenched with a solution of 
4:1 sat. NH4Cl/NH4OH (20 mL) and extracted with a mixture of 10% MeOH in DCM (3×) 
(20 mL). Combined organic layer was dried over anhydrous Na2SO4 and concentrated in 
vacuo. Purification was by prep TLC using 10:1 DCM:MeOH to give methyl 2-(5-
methoxy-2-methyl-1-(4-(1-(7-oxo-7-((trityloxy)amino)heptyl)-1H-1,2,3-triazol-4-
yl)benzyl)-1H-indol-3-yl)acetate (0.08 g, 51%), which was used for the next reaction.
The product of the first step above was dissolved in a 4:1 MeOH/H2O mixture (5 mL). 
LiOH.H2O (0.0065 g, 0.16 mmol) was added to the solution which was left to stir for 6 
hours. Solvent was evaporated off and the residue purified by prep TLC using 
EtOAc:hexane:AcOH (2:1:0.1) to give 2-(5-methoxy-2-methyl-1-(4-(1-(7-oxo-7-
((trityloxy)amino)heptyl)-1H-1,2,3-triazol-4-yl)benzyl)-1H-indol-3-yl)acetic acid (0.035 g, 
45%) as a yellow solid. Trityl deprotection was done as described for 11a. Purification was 
done using 10:1:0.1 DCM:MeOH:AcOH to give 16 as a yellow solid (0.023 g, 96%). HPLC 
retention time 10.62 minutes 1H NMR (500 MHz, DMSO-d6) δ 10.38 (s, 1H), 8.53 (s, 1H), 
7.76 (s, 2H), 7.29 (s, 1H), 7.06 (d, J = 18.4 Hz, 3H), 6.70 (d, J = 7.5 Hz, 1H), 5.40 (s, 2H), 
4.40 (s, 2H), 3.80 (d, J = 22.4 Hz, 3H), 3.55 (s, 2H), 2.32 (s, 3H), 1.92 (d, J = 30.5 Hz, 2H), 
1.49 (s, 2H), 1.28 (s, 5H). 13C NMR (126 MHz, DMSO-d6) δ 184.2, 175.2, 171.2, 163.3, 
156.1, 148.5, 144.5, 139.8, 136.8, 135.4, 131.5, 129.9, 124.8, 120.1, 115.3, 110.8, 91.9, 
65.6, 59.5, 56.1, 39.6, 35.9, 35.0, 22.4, 15.0. HRMS (ESI) [M + H]+ calculated for 
[C28H34O5N5]+ was 520.2554, found 520.2549.
4.1.18 Methyl 2-(1-(4-(1-(6-(hydroxyamino)-6-oxohexyl)-1H-1,2,3-triazol-4-
yl)benzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (17a)—Reaction of methyl 2-
(1-(4-ethynylbenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (14) (0.070 g, 0.20 mmol) 
with trityl-protected 6-azidohexanehydroxamic acid (0.10 g, 0.24 mmol) in the presence of 
DIPEA (0.070 mL, 0.43 mmol) and CuI (0.019 g, 0.10 mmol) in THF (10 mL), as described 
above for 16, gave methyl 2-(5-methoxy-2-methyl-1-(4-(1-(6-oxo-6-
((trityloxy)amino)hexyl)-1H-1,2,3-triazol-4-yl)benzyl)-1H-indol-3-yl)acetate (0.075 g, 
49%). Trityl deprotection was achieved as described for 11a. Purification was done by prep 
TLC using 10:1 DCM:MeOH to give 17a as a brown solid (0.042 g, 40%). HPLC retention 
time 12.88 minutes 1H NMR (400 MHz, CD3OD) δ 8.13 (s, 1H), 7.62 (d, J = 8.1 Hz, 2H), 
7.08 (d, J = 8.8 Hz, 1H), 6.96 (dd, J = 11.0, 5.2 Hz, 3H), 6.67 (dd, J = 8.8, 2.3 Hz, 1H), 5.26 
(s, 2H), 4.33 (t, J = 6.9 Hz, 2H), 3.76 (s, 3H), 3.71 – 3.65 (m, 2H), 3.62 (s, 3H), 2.25 (s, 3H), 
2.03 (t, J = 7.2 Hz, 2H), 1.60 (dt, J = 14.9, 7.3 Hz, 2H), 1.32 – 1.18 (m, 4H). 13C NMR (101 
MHz, CD3OD) δ 173.2, 171.5, 153.9, 138.4, 134.9, 131.8, 128.1, 126.3, 125.3, 120.6, 110.1, 
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109.3, 100.0, 54.8, 50.9, 49.9, 45.7, 31.7, 29.9, 29.7, 25.4, 24.5, 8.9. HRMS (ESI) [M + H]+ 
calculated for [C28H34O5N5]+ was 520.2554, found 520.2543.
4.1.19 Methyl 2-(1-(4-(1-(7-(hydroxyamino)-7-oxoheptyl)-1H-1,2,3-triazol-4-
yl)benzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (17b)—Trityl deprotection of 
methyl 2-(5-methoxy-2-methyl-1-(4-(1-(7-oxo-7-((trityloxy)amino)heptyl)-1H-1,2,3-
triazol-4-yl)benzyl)-1H-indol-3-yl)acetate (0.074 g, 0.095 mmol), an intermediate obtained 
during the synthesis of 16 above, was achieved as described for 11a. Purification was done 
by prep TLC using 10:1 DCM:MeOH to give 17b as a brown solid (0.025 g, 49 %). HPLC 
retention time 8.48 minutes 1H NMR (500 MHz, CD3OD) δ 8.24 (s, 1H), 7.69 (d, J = 8.0 
Hz, 2H), 7.14 (d, J = 8.8 Hz, 1H), 7.04 – 6.98 (m, 3H), 6.72 (dd, J = 8.8, 2.1 Hz, 1H), 5.36 
(s, 2H), 4.40 (t, J = 6.8 Hz, 2H), 3.81 (s, 3H), 3.75 (s, 2H), 3.67 (s, 3H), 2.32 (s, 3H), 2.06 
(m, 2H), 1.60 (m, 2H), 1.35 (m, 5H). 13C NMR (126 MHz, CD3OD) δ 173.4, 171.3, 154.3, 
147.3, 138.6, 135.0, 131.8, 129.4, 128.2, 126.3, 125.5, 120.7, 110.3, 109.5, 104.2, 100.2, 
55.0, 51.3, 50.0, 45.9, 29.7, 28.9, 28.0, 25.8, 25.1, 9.0. HRMS (ESI) [M + H]+ calculated for 
[C29H36O5N5]+ was 534.2711, found 534.2705.
4.1.20 Methyl 2-(1-(4-(1-(8-(hydroxyamino)-8-oxooctyl)-1H-1,2,3-triazol-4-
yl)benzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (17c)—Reaction of methyl 2-
(1-(4-ethynylbenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate (14) (0.074 g, 0.21 mmol) 
with trityl-protected 8-azidooctanehydroxamic acid (0.11 g, 0.26 mmol) in the presence of 
DIPEA (0.07 mL, 0.43 mmol) and CuI (0.02 g, 0.11 mmol) in THF (10 mL), as described 
above for 16, gave methyl 2-(5-methoxy-2-methyl-1-(4-(1-(8-oxo-8-
((trityloxy)amino)octyl)-1H-1,2,3-triazol-4-yl)benzyl)-1H-indol-3-yl)acetate (0.026 g, 16%). 
Trityl deprotection was achieved as described for 11a. Purification was done by prep TLC 
using 10:1 DCM:MeOH to give 17c as a brown solid (0.017 g, 92%). HPLC retention time 
9.92 minutes 1H NMR (500 MHz, CD3OD) δ 8.26 (s, 1H), 7.72 (d, J = 7.2 Hz, 2H), 7.16 (d, 
J = 8.7 Hz, 1H), 7.04 (s, 3H), 6.74 (d, J = 8.6 Hz, 1H), 5.38 (s, 2H), 4.42 (s, 2H), 3.83 (s, 
3H), 3.77 (s, 2H), 3.69 (s, 3H), 2.34 (s, 4H), 1.95 (s, 2H), 1.61 (s, 2H), 1.34 (ms, J = 24.6 
Hz, 8H). 13C NMR (126 MHz, CD3OD) δ 175.3, 170.3, 156.4, 149.2, 140.7, 137.1, 133.8, 
131.5, 130.3, 128.4, 127.5, 122.8, 112.4, 111.6, 106.2, 102.3, 57.1, 53.1, 52.1, 48.0, 31.8, 
30.8, 30.3, 28.1, 27.4, 24.7, 11.1. HRMS (ESI) [M + H]+ calculated for [C30H38O5N5]+ was 
548.2867, found 548.2855.
4.2 Cell viability assay
All cell lines used in this study (Du-145, LNCaP, HCT-116, A549, MCF-7 and Vero) were 
maintained in the respective media recommended by ATCC. All the media used were 
supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA) and 
1% Pen. Strep. Prior to treatment with various drug concentrations and subsequent 
incubation for 72 hours, cells were incubated in a 96 well plate for 24 hours. Cell viability 
was measured using the MTS assay protocol as described by the manufacturer. For all drugs 
tested, DMSO concentration was maintained at 0.1% for experiments in LNCaP, HCT-116 
and DU-145; and at 1% for experiments in other cell lines. Data was analyzed using the 
LOGIT function. GRAPHPAD prism software was used to generate all growth-inhibition 
curves.
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4.3 Cell cycle analysis
LNCaP cells were seeded onto 6-well plates at a density of 1×106 cells in 5 mL of media, 
and incubated in a humidified 5% CO2 atmosphere at 37 °C overnight. Following aspiration 
of media, fresh media containing drugs were added to the cells and incubated for 24 h. After 
incubation, cells were trypsinized, harvested and fixed with 70% EtOH. Fixed cells were 
stained with freshly prepared PI solution containing RNAse A, and then analyzed on flow 
cytometer (BD FACS Acuri, BD Bioscience, San Jose, CA, USA). Unstained cells were 
used as control. Each experiment was performed in triplicate.
4.4 Western blots analysis
LNCaP cells (106 cells/dish) were seeded in petri dishes 24 hour prior to treatment with 
various concentrations of compounds for 24h. Thereafter, media was removed and cells were 
washed with chilled 1× PBS buffer and resuspended in CelLyticM buffer containing a 
cocktail of protease inhibitor (Sigma-Aldrich, St. Louis, MO, USA). Protein concentration 
was determined through Bradford protein assay. Equal amount of protein was then loaded 
onto an SDS-page gel (Bio-Rad, Hercules, CA, USA) and resolved by electrophoresis at a 
constant voltage of 100 V for 2 h. The gel was transfered onto a nitrocellulose membrane 
and probed for acetylated tubulin, acetyl H4, AR, COX-2 and actin as loading control.
4.5 HDAC inhibition
The HDAC activity in presence of our compounds was assessed using the SAMDI mass 
spectrometry. As a label-free technique, SAMDI is compatible with a broad range of native 
peptide substrates without requiring potentially disruptive fluorophores. To obtain IC50 
values, we incubated isoform-optimized substrates (20 µM for HDACs 1–2, 6 and 50 µM for 
HDAC 8) with enzyme (70 nM (HDAC 1), 100 nM (HDAC 2), 50 nM (HDAC 3), 60 nM 
(HDAC 6), 500 nM (HDAC 8)) and inhibitor (at concentrations ranging from 10 nM to 1.0 
mM) in 96-well microtiter plates at 30 °C (24 h (HDAC 1), 24 h (HDAC 2), 5 h (HDAC 3), 
20 h (HDAC 6), 2.5 h (HDAC 8)). Solution-phase deacetylation reactions were quenched 
with trichostatin A (TSA) and transferred to SAMDI plates to immobilize the substrate 
components. SAMDI plates were composed of an array of self-assembled monolayers 
(SAMs) presenting maleimide in standard 384-well format for high-throughput handling 
capability. Following immobilization, plates were washed to remove buffer constituents, 
enzyme, inhibitor, and any unbound substrate and analyzed by MALDI mass spectrometry 
using automated protocols44. Deacetylation yields in each triplicate sample were determined 
from the integrated peak intensities of the molecular ions for the substrate and the 
deacetylated product ion by taking the ratio of the former over the sum of both. Yields were 
plotted with respect to inhibitor concentration and fitted to obtain IC50 values for each 
isoform–inhibitor pair.
4.6 COX inhibition assay
In vitro COX inhibitory activity was evaluated using Cayman’s COX Fluorescent Inhibitor 
Screening Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA) following the 
manufacturer’s protocol. Briefly, ovine COX-1 and human recombinant COX-2 enzymes 
were incubated with stock solutions of our compounds and heme for 15 minutes at room 
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temperature, after which a resorufin precursor was added and incubated for another 15 
minutes at room temperature. The reaction was started by the adding arachidonic acid and 
left to proceed for 2 minutes. Fluorescence was measured at a 530 nm excitation wavelength 
and a 595 nm emission wavelength using a micro plate reader (Envision, PerkinElmer). Data 
was analyzed using the LOGIT function.
4.7 Molecular Docking Analysis
In silico docking was performed using Autodock Vina45 run through PyRx to manage the 
workflow and PyMol to visualize the results, as described previously19d. Briefly, ligands 
were prepared by first generating an energy minimized 3D structure in ChemBioDraw3D. 
This was followed by processing with Autodock Tools 1.5.4. Docking runs were performed 
within a 25–30 Å cubic search space surrounding the binding pocket.
4.8 Intracellular PGE2 measurement
HeLa cells (3×105 cells/dish) were seeded in 6-well plates 24 hours prior to treatment with 
various concentrations of tested compounds. After incubation for 24 hours, the cell culture 
media was taken and centrifuged at 14,000 × g for 10 minutes, to remove cellular debris. 
PGE2 concentration was determined by using PGE2 ELISA Kit-monoclonal (catalog number 
514010). The assay was performed as recommended by the manufacturer. Briefly, serial 
dilution of PGE2 standard and 50 µL of each sample were added to the recommended 
amount PGE2 antiserum and acetylcholinesterase tracer and incubated at 4°C for 18 hours. 
The wells were emptied and washed five times with wash buffer. Thereafter, 200 µL of 
Ellman’s reagent containing substrate for acetylcholinesterase was added. The reaction was 
developed at room temperature for 2 hours on a slow shaker. Plates was read at 405 nm on a 
micro plate reader (Envision, PerkinElmer). Data was analyzed using the LOGIT function. 
GRAPHPAD prism software was used to generate graph and perform statistical analyses. 
Individual runs were normalized with respect to the control, and PGE2 suppression 
expressed in terms of percentage.
4.9 Anti-inflammatory activity assay
NF-κB activity was measured using luciferase assay. BEAS-2B cells were transfected with 
NF-κB luciferase reporter construct in pGL3 basic vector46. Forty hours after transfection, 
the cells were treated with test compounds for 1 hour followed by stimulation with NTHi for 
5 hours. The cells were then lysed with cell lysis buffer (250 mM Tris-HCl (pH 7.5), 0.1% 
Triton-X, 1 mM DTT) and luciferase activity was measured by using luciferase assay system 
(Promega). Relative luciferase activity (RLA) was determined using the following equation: 
RLA = luciferase unit of the cells treated with NTHi and inhibitors/luciferase unit of the 
cells treated with mock.
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Figure 1. 
HDACi in use in the clinic
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Figure 2. 
Representative examples of US FDA approved NSAIDs
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Figure 3. 
Crystal structures showing (a) binding of celecoxib within COX-2 (PDB code 3LN1) 
showing SO2NH2 modification site, and (b) binding of celecoxib within COX-2 (PDB code 
3LN1) showing CF3 modification site, (c) bindining of indomethacin within COX-2 (PDB 
code 4COX) showing carboxylate modification site.
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Figure 4. 
(a) HDACi pharmacophoric model integrated in vorinostat structure. (b) Designed dual-
acting COXi-HDACi compounds – (i) Celecoxib-based HDACi (series 1), (ii and iii) 
Celecoxib-based HDACi (series 2 and 3) (iv and v) Indomethacin-based HDACi (series 4 
and 5).
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Figure 4. 
Docking output of NSAID-HDACi conjugates overlaid with crystal structure of celecoxib 
and indomethacin in COX-2: i) series 1 conjugates: 2a (blue), 2b (magenta), 2c (yellow) and 
celecoxib (red); ii) series 2 and 3 conjugates: 7a (blue), 7b (magenta), 7c (yellow) 8 (green); 
iii) series 4 conjugates: 11a (blue), 11b (magenta), 11c (yellow), and indomethacin (red); iv) 
surface representation of series 4 conjugates: 11a (blue), 11b (magenta), 11c (yellow), and 
indomethacin (red); v) series 5 conjugates: 17a (blue), 17b (magenta), 17c (yellow), and 
indomethacin (red); vi) surface representation of series 5 conjugates: 17a (blue), 17b 
(magenta), 17c (yellow), and indomethacin (red).
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Figure 5. 
Antiproliferative activity of combination of equimolar concentration of respective NSAIDs 
and SAHA compared to equal concentration of appropriate bifunctional compounds in a) 
LNCaP; b) DU-145; and c) VERO cell lines.
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Figure 6. 
Western blot analysis of acetylated tubulin, AR and COX-2 in LNCaP following treatment 
for 24hr. Lanes: 1, Control (DMSO); 2, SAHA (10 µM); 3, 2b (2 µM); 4, 2b (10 µM); 5, 11b 
(2 µM); 6, 11b (10 µM); 7, 17b (1.5 µM); 8, celecoxib (10 µM); 9, indomethacin (10 µM).
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Figure 7. 
Intracellular COX-2 inhibition is evidenced by attenuation of prostaglandin E2 (PGE2) 
production. HeLa cells were treated with each of the tested compounds at 10× IC50 (Table 2) 
for 24hrs and PGE2 level was measured. Celecoxib and indomethacin were tested at 0.1 µM 
and 0.2 µM respectively. Data are representative of three independent experiments.
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Figure 8. 
Effect of SAHA, 2b, 8, 11b, 17b, celecoxib and indomethacin on LNCaP cell cycle 
progression.
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Figure 9. 
Representative NSAID-HDACi conjugates inhibit NF-κB activation. BEAS-2B cells, 
transfected with NF-κB luciferase construct, were pre-treated with compounds 8, 17b or 
SAHA at 1 µM for 1hr and stimulated with NTHi for 5hr, and NF-kB promoter activity was 
then measured by performing luciferase assay. Data are mean ± SD (n=3). *p<0.05. 
Statistical analysis was performed using Student’s t-test. Data are representative of three 
independent experiments. CON = BEAS-2B cells treated with PBS control; NTHi = 
BEAS-2B cells treated with NTHi.
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Scheme 1. 
Synthesis of series 1 celecoxib-HDACi conjugates
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Scheme 2. 
Synthesis of series 2 and 3 celecoxib-HDACi conjugates
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Scheme 3. 
Synthesis of series 4 celecoxib-HDACi conjugates
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Scheme 4. 
Synthesis of series 5 celecoxib-HDACi conjugates
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